Mesenchymal tumors are characterized by being more prone to recurrence, which of course is related to the size of the primary tumor, the primary site, and the surgical treatment. Generally mesenchymal tumors are malignant and their malignancy is related to the size of the tumor and the number of nuclear schizophrenic images (which will be described in the pathology report). Mesenchymal tumors over 5 cm should be above moderate risk and insensitive to chemoradiotherapy. Patients with limited GIST who have undergone surgical treatment have an overall 5-year survival rate of 40-55% after complete resection, with a highly variable recurrence rate in the fifth postoperative year, ranging from 2-15% for low-risk primary tumors and 70-90% for high-risk cases. There are no specific serum markers to detect GIST recurrence. The typical sites of tumor recurrence are the surgically resected bed, liver and peritoneum. Pulmonary metastases are rare. Therefore, the standard practice is to perform imaging (abdominopelvic CT) every 3-6 months for 5 years after surgery and to evaluate annually thereafter. Regular postoperative reviews and recurrences can sometimes be surgically removed if they do not invade vital organs. Oral imatinib (Gleevec) is effective if financial situation allows, but very expensive.